1. Home
  2. EXAS vs VIV Comparison

EXAS vs VIV Comparison

Compare EXAS & VIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • VIV
  • Stock Information
  • Founded
  • EXAS 1995
  • VIV 1973
  • Country
  • EXAS United States
  • VIV Brazil
  • Employees
  • EXAS N/A
  • VIV N/A
  • Industry
  • EXAS Medical Specialities
  • VIV Telecommunications Equipment
  • Sector
  • EXAS Health Care
  • VIV Telecommunications
  • Exchange
  • EXAS Nasdaq
  • VIV Nasdaq
  • Market Cap
  • EXAS 10.5B
  • VIV 12.6B
  • IPO Year
  • EXAS N/A
  • VIV 1998
  • Fundamental
  • Price
  • EXAS $49.26
  • VIV $9.16
  • Analyst Decision
  • EXAS Strong Buy
  • VIV Buy
  • Analyst Count
  • EXAS 17
  • VIV 3
  • Target Price
  • EXAS $72.31
  • VIV $10.47
  • AVG Volume (30 Days)
  • EXAS 1.9M
  • VIV 724.1K
  • Earning Date
  • EXAS 02-19-2025
  • VIV 02-25-2025
  • Dividend Yield
  • EXAS N/A
  • VIV 5.13%
  • EPS Growth
  • EXAS N/A
  • VIV 19.08
  • EPS
  • EXAS N/A
  • VIV 0.60
  • Revenue
  • EXAS $2,758,867,000.00
  • VIV $10,063,607,239.00
  • Revenue This Year
  • EXAS $12.09
  • VIV $10.18
  • Revenue Next Year
  • EXAS $11.24
  • VIV $6.37
  • P/E Ratio
  • EXAS N/A
  • VIV $15.11
  • Revenue Growth
  • EXAS 10.37
  • VIV 6.98
  • 52 Week Low
  • EXAS $40.62
  • VIV $7.47
  • 52 Week High
  • EXAS $79.62
  • VIV $11.43
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 33.51
  • VIV 62.23
  • Support Level
  • EXAS $45.94
  • VIV $9.03
  • Resistance Level
  • EXAS $51.75
  • VIV $9.45
  • Average True Range (ATR)
  • EXAS 2.13
  • VIV 0.17
  • MACD
  • EXAS -0.30
  • VIV 0.00
  • Stochastic Oscillator
  • EXAS 32.20
  • VIV 64.46

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About VIV Telefonica Brasil S.A. (Each representing One Common Share)

Telefonica Brasil, known as Vivo, is the largest wireless carrier in Brazil with 100 million customers, which is equal to about 39% market share. The firm is strongest in the postpaid business, where it has 65 million customers, or about 41% share of this market. Wireless services and equipment contribute about 70% of total revenue. Vivo is the incumbent fixed-line telephone operator in Sao Paulo state and, following the acquisition of GVT, the owner of an extensive fiber network across the country. The firm provides internet access to 7 million households on this network. The firm also sells pay-tv and phone services to its fixed-line customers. Finally, corporate data and IT services, including cloud computing support, contribute about 8% of total revenue.

Share on Social Networks: